Sequana Medical announces H1 2023 results and provides business update
September 14, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international liver congress / on track to file...
Sequana Medical Notice of 2023 Half-year Results and Business Update
September 06, 2023 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 6 September 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure...
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
July 10, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext...
1,000th alfapump® implant completed
July 06, 2023 01:00 ET
|
Sequana Medical NV
Extensive real world alfapump experience derisks planned US & Canadian launchStrong clinical alfapump profile demonstrated in North American POSEIDON studyAll approvals received to commence US...
Sequana Medical announces results of Special General Meeting of Shareholders
June 26, 2023 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA)...
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
June 21, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION21 June 2023, 07:00 am CEST Data presented at EASL Congress 2023 alfapump was effective in the control of ascites, virtually eliminating...
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
June 19, 2023 12:00 ET
|
Sequana Medical NV
PRESS RELEASE Poster presentation at EASL by Dr. Florence Wong on 21 June 2023; selected for additional poster presentation on 23 June 2023Conference call with live webcast by Sequana Medical on 21...
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
June 16, 2023 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and...
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
May 26, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION26 May 2023, 07:00 am CEST Ghent, Belgium – 26 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
Sequana Medical announces results of Annual General Meeting of Shareholders
May 25, 2023 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION25 May 2023, 06:00 pm CEST Ghent, Belgium – 25 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...